Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Braden

Neuromusculoskeletal Medicine & OMM Grand Rapids, MI Doctor of Osteopathy

NPI 1912490905 CMS profile 5230508

3300 Eagle Run Dr Ne Ste 103, Grand Rapids, MI 49525

Open in the dashboard

General payments

$7,926

527 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Braden of Grand Rapids, MI is reported in the CMS Open Payments database as having received $7,926 across 527 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Neuromusculoskeletal Medicine & OMM profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,593 101
2024 General $1,990 149
2023 General $2,763 187
2022 General $1,219 73
2021 General $274 12
2019 General $88 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Braden
  • Neuromusculoskeletal Medicine & OMM median
  • Middle half of Neuromusculoskeletal Medicine & OMM
  • National median

In program year 2025, general payments to Mark Braden were reported at $1,593. Among 217 Neuromusculoskeletal Medicine & OMM profiles paid that year, the median was $119 and the middle half received between $36 and $380.

Show as a table
Year Mark Braden Neuromusculoskeletal Medicine & OMM median Middle half National median
2019 $88 $92 $27–$283 $163
2020 $0 $85 $20–$411 $114
2021 $274 $120 $32–$548 $132
2022 $1,219 $96 $32–$518 $149
2023 $2,763 $92 $33–$328 $160
2024 $1,990 $122 $35–$378 $164
2025 $1,593 $119 $36–$380 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $2,289 248 payments
  2. UCB, Inc. $1,150 56 payments
  3. Amgen Inc. $1,116 71 payments
  4. ANI Pharmaceuticals, Inc. $558 25 payments
  5. Mallinckrodt Hospital Products Inc. $430 19 payments
  6. AstraZeneca Pharmaceuticals LP $411 20 payments
  7. Lilly USA, LLC $274 13 payments
  8. Organon LLC $225 11 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $187 9 payments
  10. Janssen Scientific Affairs, LLC $184 2 payments
  11. Other $1,102 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,736 525 payments
  2. Education $190 2 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $2,377 240 payments
  2. SIMPONI ARIA $1,225 157 payments
  3. Cimzia $843 42 payments
  4. TAVNEOS $445 25 payments
  5. ACTHAR $430 19 payments
  6. SAPHNELO $411 20 payments
  7. PURIFIED CORTROPHIN GEL $408 16 payments
  8. Bimzelx $306 14 payments
  9. AVSOLA $287 14 payments
  10. TALTZ $274 13 payments
  11. Other $2,965 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$38,309

Medicare's payments for the services billed

Medicare patients

69

Average age 67

Services billed

2,067

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 61%
Depression 46%
Osteoporosis 42%
Diabetes 26%
Ischemic heart disease 17%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$299 — —
PURIFIED CORTROPHIN GEL
$277 — —
SIMPONI ARIA
$264 — —
Cimzia
$226 — —
TAVNEOS
$167 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

527 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuromusculoskeletal Medicine & OMM in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record